News

Vivus has made a surprise announcement that its only-just elected chief executive Tony Zook is resigning due to health concerns.

MRC Technology (MRCT) and Arthritis Research UK are seeking funding proposals from UK-based academic researchers to validate small-molecule or antibody targets in pathways significant to the development or progression of musculoskeletal conditions.

England’s National Institute for Health Research (NIHR) has launched an online showcase of its clinical-research efforts in dementia and other neurodegenerative diseases to mark the start of World Alzheimer’s Month.

Many private hospitals in the UK face little competition, leading to higher private medical insurance premiums and charges for private patients, says the Competition Commission.

The UK’s Acacia Pharma has raised £15 million to finance late-stage development of its treatments designed to prevent nausea and vomiting in cancer patients.

Twice as many UK patients achieve LDL-cholesterol target levels than patients in Germany, and this may be due to a healthcare system which “rewards” rather than “punishes” GPs, new research suggests.

The high prevalence of conspiracy theories in the US around the origins of HIV and efforts to combat the virus is not a barrier to participation in trials of vaccines for the human immunodeficiency virus, a new study indicates.

GlaxoSmithKline has been accused of co-ordinating widescale bribery in China rather than individuals acting on their own initiative.

Johnson & Johnson has filed siltuximab on both sides of the Atlantic for a rare blood disorder.

A tiny pain-free jab every two weeks could be the future of cholesterol-lowering for high-risk patients, according to clinical researchers gathered in Amsterdam for the European Society of Cardiology congress.

The European Commission has approved Bayer’s Stivarga for the treatment of adults with metastatic colorectal cancer who have previously been treated with, or are not suitable for, available therapies.

GlaxoSmithKline’s Tafinlar has been approved by the European Commission as an oral treatment for unresectable or metastatic melanoma in adults with a BRAF V600 mutation.

Meda of Sweden has hit the acquisition trail and unveiled plans to buy Acton Pharmaceuticals in a deal that could be worth up to $200 million to the US respiratory specialist.

Investigators have presented full results from a late-stage study which sheds more light on Sanofi’s decision to halt development of its injectable factor Xa inhibitor otamixaban.

Europe’s regulators had approved a new formulation of Roche’s breast cancer drug Herceptin which will slash the time needed to administer the blockbuster.